Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 5

From BugSigDB


Reviewed Marked as Reviewed by Chloe on 2023-12-14

Curated date: 2023/12/10

Curator: Yjung24

Revision editor(s): Yjung24

Subjects

Location of subjects
Norway
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Treatment Treatment,treatment
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Inflammatory bowel disease patients treated with conventional therapy
Group 1 name Corresponds to the case (exposed) group for case-control studies
Inflammatory bowel disease patients treated with biological therapy
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
58% of inflammatory bowel disease patients were later treated with biologic therapy due to failure to induce remission with conventional treatments or relapse after primary induction.
Group 0 sample size Number of subjects in the control (unexposed) group
46
Group 1 sample size Number of subjects in the case (exposed) group
64

Lab analysis

Sequencing type
PCR
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
Not specified
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
RT-qPCR

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Mann-Whitney (Wilcoxon)
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No


Signature 1

Reviewed Marked as Reviewed by Chloe on 2023-12-14

Curated date: 2023/12/10

Curator: Yjung24

Revision editor(s): Yjung24

Source: Table 3

Description: Bacterial species exhibiting deviating abundances between medical therapy groups and between groups with high and low calprotectin levels.

Abundance in Group 1: decreased abundance in Inflammatory bowel disease patients treated with biological therapy

NCBI Quality ControlLinks
Bifidobacterium adolescentis
Bifidobacterium bifidum
Agathobacter rectalis
Roseburia hominis
Roseburia inulinivorans
Ruminococcus bromii
Bacteroides finegoldii
Bacteroides intestinalis
Bacteroides cellulosilyticus
Paraprevotella clara

Revision editor(s): Yjung24

Signature 2

Reviewed Marked as Reviewed by Chloe on 2023-12-14

Curated date: 2023/12/10

Curator: Yjung24

Revision editor(s): Yjung24

Source: Table 3

Description: Bacterial species exhibiting deviating abundances between medical therapy groups and between groups with high and low calprotectin levels.

Abundance in Group 1: increased abundance in Inflammatory bowel disease patients treated with biological therapy

NCBI Quality ControlLinks
Mediterraneibacter gnavus
Phocaeicola vulgatus

Revision editor(s): Yjung24